购物车
- 全部删除
- 您的购物车当前为空
BMS CCR2 22 是一种有效的选择性 CC 型趋化因子受体2拮抗剂,钙通量 IC50为 18 nM,趋化性 IC50为1 nM,结合 IC50为5.1 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
BMS CCR2 22 是一种有效的选择性 CC 型趋化因子受体2拮抗剂,钙通量 IC50为 18 nM,趋化性 IC50为1 nM,结合 IC50为5.1 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 870 | 现货 | |
5 mg | ¥ 1,720 | 现货 | |
10 mg | ¥ 2,230 | 现货 | |
25 mg | ¥ 3,730 | 现货 | |
50 mg | ¥ 4,910 | 现货 | |
100 mg | ¥ 6,780 | 现货 | |
200 mg | ¥ 9,130 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 2,270 | 现货 |
产品描述 | BMS CCR2 22 is a potent and selective antagonist of CCR2 with calcium flux IC50 of 18 nM, chemotaxis IC50 of 1 nM, and binding IC50 of 5.1 nM. |
靶点活性 | CCR2:5.1 nM |
体外活性 | BMS CCR2 22 inhibits the internalization of hMCP1_AF647 (IC50 = 2 nM)[2]. HAoECs with BMS CCR2 22 before MCP-1 increases the cell surface levels of VCAM-1 from 72.8 to 160% and PECAM1 from 97.2 and 127%[3]. |
分子量 | 593.66 |
分子式 | C28H34F3N5O4S |
CAS No. | 445479-97-0 |
Smiles | CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F |
密度 | 1.33 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 225.0 mg/mL (379.0 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容